


WHAT IS CLAIMED IS

1. A compound of formula (I):



wherein:

q is 1 or 2;

r is 1 or 2;

R¹ is hydrogen or alkyl;

R² is thiazolyl, isothiazolyl or isoxazolyl;

R^{3a} and R^{3b} are each independently hydrogen or alkyl;

each R⁴ is independently halo or alkyl;

R⁵ is halo;

each R⁶ is independently halo or alkoxy;

R⁷ is azabicyclo[2.2.1]heptanylalkyl or R⁷ is ((methyl)(prop-2-yl)amino)alkyl when r is 2
and at least one R⁶ is alkoxy;

as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

2. The compound of Claim 1 wherein R⁷ is azabicyclo[2.2.1]heptanylalkyl.

3. The compound of Claim 2 wherein R² is isothiazolyl.

4. The compound of Claim 3 selected from:

4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluorobenzyl)amino)-2,6-difluoro-N-(isothiazol-3-yl)benzenesulfonamide; and

4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluorobenzyl)amino)-2,3-difluoro-N-(isothiazol-3-yl)benzenesulfonamide 2,2,2-trifluoroacetate.

5. The compound of Claim 2 wherein R² is thiazolyl.

6. The compound of Claim 5 wherein *r* is 1.

7. The compound of Claim 6 selected from:

- 4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluorobenzyl)amino)-2,3-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluorobenzyl)amino)-3-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide 2,2,2-trifluoroacetate;
4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluorobenzyl)amino)-2-fluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide 2,2,2-trifluoroacetate; and
4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluorobenzyl)amino)-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide 2,2,2-trifluoroacetate.

8. The compound of Claim 5 where *r* is 2.

9. The compound of Claim 8 selected from:

- 4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-3,6-difluorobenzyl)amino)-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluoro-3-methoxybenzyl)amino)-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide 2,2,2-trifluoroacetate;
4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluoro-3-methoxybenzyl)amino)-2,3-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide 2,2,2-trifluoroacetate;
54-((2-(1-(7-azabicyclo[2.2.1]heptan-7-yl)ethyl)-3,6-difluorobenzyl)amino)-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide 2,2,2-trifluoroacetate;
(*S*)-4-((2-(1-(7-azabicyclo[2.2.1]heptan-7-yl)ethyl)-3,6-difluorobenzyl)amino)-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide; and
(*R*)-4-((2-(1-(7-azabicyclo[2.2.1]heptan-7-yl)ethyl)-3,6-difluorobenzyl)amino)-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide.

10. The compound of Claim 2 wherein *R*² is isoxazolyl.

11. The compound of Claim 10 selected from:

- 4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluorobenzyl)amino)-2,6-difluoro-*N*-(isoxazol-3-yl)-3-methylbenzenesulfonamide; and
4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluorobenzyl)amino)-2-fluoro-*N*-(isoxazol-3-yl)-3-methylbenzenesulfonamide 2,2,2-trifluoroacetate.

12. The compound of Claim 1 where R^7 is ((methyl)(prop-2-yl)amino)alkyl, provided that r is 2 and at least one R^6 is alkoxy.
13. The compound of Claim 12 wherein R^2 is isothiazolyl.
14. The compound of Claim 12 wherein R^2 is thiazolyl.
15. The compound of Claim 14 selected from:
2,6-difluoro-4-((6-fluoro-2-((isopropyl(methyl)amino)methyl)-3-methoxybenzyl)amino)-
N-(thiazol-4-yl)benzenesulfonamide;
2,6-difluoro-4-((6-fluoro-3-isopropoxy-2-
((isopropyl(methyl)amino)methyl)benzyl)amino)-*N*-(thiazol-4-
yl)benzenesulfonamide;
2,3-difluoro-4-((6-fluoro-2-((isopropyl(methyl)amino)methyl)-3-methoxybenzyl)amino)-
N-(thiazol-4-yl)benzenesulfonamide;
5-chloro-2-fluoro-4-((6-fluoro-2-((isopropyl(methyl)amino)methyl)-3-
methoxybenzyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide 2,2,2-
trifluoroacetate; and
2-fluoro-4-((6-fluoro-2-((isopropyl(methyl)amino)methyl)-3-methoxybenzyl)amino)-5-
methyl-*N*-(thiazol-4-yl)benzenesulfonamide 2,2,2-trifluoroacetate.
16. The compound of Claim 12 wherein R^2 is isoxazolyl.
17. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of Claims 1-16, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
18. A method of treating a disease or a condition associated with $Na_v1.6$ activity in a mammal wherein the disease or condition is epilepsy and/or epileptic seizure disorder and wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of any one of Claims 1-16, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

19. A method of decreasing ion flux through $\text{Na}_v1.6$ in a mammalian cell, wherein the method comprises contacting the cell with a compound of any one of Claims 1-16, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

20. A method of selectively inhibiting a first voltage-gated sodium channel over a second voltage-gated sodium channel in a mammal, wherein the method comprises administering to the mammal a modulating amount of a compound of any one of Claims 1-16, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

21. The method of Claim 18 wherein the first voltage-gated sodium channel is $\text{Na}_v1.6$.

22. The method of Claim 18 wherein the second voltage-gated sodium channel is $\text{Na}_v1.5$.

23. The method of Claim 16 wherein the second voltage-gated sodium channel is $\text{Na}_v1.1$.